On March 17, 2025, Mangoceuticals' shareholders approved amendments to the Series B Convertible Preferred Stock, reducing the conversion price to $1.50 per share and modifying the 2022 Equity Incentive Plan. The amendments allow for the issuance of up to 26 million shares under the plan and were approved with significant majority votes.